摘要
目的探讨奥沙利铂联合表阿霉素、替吉奥治疗晚期胃癌的临床疗效及不良反应。方法本院收治的晚期胃癌患者46例应用奥沙利铂135mg／m2，d1，静脉滴注；表阿霉素50mg／m2，d1，静注；替吉奥20mgbid，d1-14。每3周重复，连用2个周期。观察完成2个周期以上的化疗患者的临床疗效及毒副反应发生情况。结果治疗总有效率为54．35％。毒副反应中消化道反应（发生率86．96％）、骨髓抑制（发生率71．74％）和脱发（发生率100．00％）为主要毒副反应。结论奥沙利铂联合表阿霉素、替吉奥治疗晚期胃癌，疗效较好，毒性发生率低，值得临床进一步推广使用。
Objective To investigate the Xxaliplatin combined with Epirubicin and S- 1 for the treatment of advanced gastric cancer and adverse reactions. Methods Forty - six patients were approached with advanced gastric cancer application Oxaliplatin 135 mg/m2, dl, intravenous infu- sion; Epirubicin 50 mg/m2, dl, intravenous; for Gio 20 mg bid, d1-14. It was repeated every 3 weeks for two cycles. Clinical efficacy and toxicity at the completion of 2 cycles of chemotherapy were observed. Results The total effective rate was 54.35 %. The incidence rate of toxicity in the gastrointestinal reactions was 86.96 （t6, bone marrow suppression 71.74 % and alopecia 100.00 % as the main toxicity. Conclusion Oxaliplatin in combination with Epirubicin and S- 1 for treatment of advanced gastric cancer have better efficacy and low toxicity, the use of which is worthy further promoting.
出处
《实用临床医药杂志》
CAS
2011年第23期85-86,共2页
Journal of Clinical Medicine in Practice
